For years, Foundry Row's biotech story has been one of expansion: more hiring, more funding rounds, more lab space. Ridgeline Therapeutics is now writing a different chapter, cutting 45 jobs after a clinical trial result its executives call disappointing but not fatal.
The company said its lead therapy candidate, aimed at a rare autoimmune condition, did not meet its primary efficacy endpoint in a Phase 2 trial, results Ridgeline disclosed to investors this week. Chief Executive Aaron Whitlock said the company would cut 45 positions, concentrated in the manufacturing and clinical-operations teams that had been staffed up to support the candidate’s anticipated advancement to a larger trial, while preserving its research division intact.
A setback the company says isn’t fatal
“This is a real setback, and I’m not going to pretend it isn’t,” Whitlock said. “But a Phase 2 miss on one candidate isn’t the end of a company with three other programs in earlier stages. We built up specifically to support this candidate’s next phase, and now we have to right-size to where the science actually is, not where we hoped it would be.” Whitlock said affected employees would receive severance and job placement assistance, including introductions to Kestrel Biologics, which he said has expressed informal interest in some of the laid-off manufacturing technicians.
Kestrel Biologics Chief Executive Elena Marchetti confirmed her company has reached out to Ridgeline about potential hires, calling it a practical response to a labor market where trained biotech technicians remain scarce even amid one company’s setback. “It would be strange for us to sit on open technician positions while a building three blocks away is laying off people with exactly that training,” Marchetti said. “This is an unusual case where one company’s bad week can actually help solve another company’s hiring problem.”
A Phase 2 miss on one candidate isn’t the end of a company with three other programs in earlier stages. We have to right-size to where the science actually is, not where we hoped it would be.
Aaron Whitlock, CEO, Ridgeline Therapeutics
A reality check for the cluster’s growth story
Dr. Samuel Iyer, the Bellwater State University labor economist who has closely tracked Foundry Row’s biotech employment growth, said the layoffs offer a useful, if uncomfortable, corrective to a narrative that has treated the cluster’s expansion as inevitable. “Every report on this cluster, including ones I’ve contributed to, has emphasized the job growth,” Iyer said. “Ridgeline’s trial result is a reminder that biotech isn’t a steady manufacturing business. It’s built on science that sometimes doesn’t work, and when it doesn’t, the jobs built around the assumption that it would work disappear along with it.”
Theresa Nakamura, executive director of the Bellwater Chamber of Commerce, said she has fielded calls from several affected employees since the layoffs were announced and has directed some toward openings at Kestrel Biologics and smaller Forge Bellwater-affiliated firms. “The good news, if there is any, is that this happened in a labor market where the skills these people have are genuinely in demand elsewhere in the same neighborhood,” Nakamura said. “That wouldn’t have been true five years ago, before this cluster existed at all.”
Whitlock said the company remains committed to Foundry Row and does not anticipate further layoffs barring another negative trial result, though he acknowledged the company’s next major data readout, expected within the year for a separate candidate targeting a different condition, now carries additional weight. “I’d be lying if I said the next result doesn’t matter more to this company than it would have mattered a month ago,” Whitlock said.
One laid-off manufacturing technician, who asked not to be named because she is still negotiating severance terms, said she had moved to Bellwater specifically for the Ridgeline job two years ago and was now weighing whether to stay in the city given the uncertainty. “I believed the pitch that this was a growing industry with room for people like me,” she said. “I still think that’s true generally. It just wasn’t true for me at this particular company this particular month.”
- 45 positions cut, roughly a fifth of Ridgeline’s Bellwater workforce
- Cuts concentrated in manufacturing and clinical-operations teams
- Research division and three earlier-stage drug programs remain intact
- Kestrel Biologics has expressed interest in hiring some affected technicians
Whitlock said the company has scheduled a town hall for remaining employees to address morale concerns and reaffirm its commitment to its other drug programs. “I don’t want anyone walking around this building thinking the whole thing is on shaky ground,” he said. “It isn’t. But I understand why a layoff, even a targeted one, makes people nervous regardless of what I tell them about the rest of the pipeline.”
Nakamura said the chamber has offered to help coordinate a job fair specifically for affected Ridgeline employees, inviting Kestrel Biologics along with several smaller Forge Bellwater-affiliated biotech firms that have expressed interest in hiring displaced workers. She said the chamber’s goal is to keep as many of the laid-off technicians as possible within Bellwater’s biotech workforce rather than losing them to opportunities in other cities, a risk she said grows the longer any of them remain unemployed.